Antidepressant and QT interval prolongation, how should we look at this issue? Focus on citalopram

Expert Opinion on Drug Safety

Volumn 13, Issue 2, 2014, Pages 197-205

  Pae, Chi Un ^a,b   Wang, Sheng Min ^a   Lee, Soo Jung ^a   Han, Changsu ^c   Patkar, Ashiwn A ^b   Masand, Prakash S ^d  

^a The Catholic University of Korea   (South Korea)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Korea University   (South Korea)

^d Global Medical Education Inc   (United States)

Author keywords

Antidepressant; Benefit; Citalopram; Depression; QT interval prolongation; Risk

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; MIRTAZAPINE; NORTRIPTYLINE; PAROXETINE; SERTRALINE; VENLAFAXINE;

CARDIOTOXICITY; CARDIOVASCULAR RISK; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HEART ARRHYTHMIA; HUMAN; QT PROLONGATION; REVIEW; SUDDEN CARDIAC DEATH;

ANTIDEPRESSIVE AGENTS; CITALOPRAM; LONG QT SYNDROME; RISK FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84892747205     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2013.840583     Document Type: Review

References (59)

1. Nielsen J, Graff C, Kanters JK, et al. Assessing QT interval prolongation and its associated risks with antipsychotics. CNS Drugs 2011;25(6): 473-90
2. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004;350(10): 1013-22
3. Glassman AH. Schizophrenia, antipsychotic drugs, and cardiovascular disease. J Clin Psychiatry 2005;66(Suppl 6): 5-10
4. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. 3rd edition American Psychiatric Publishing, Arlington, VA, 2011
5. Glassman AH, Preud'homme XA. Review of the cardiovascular effects of heterocyclic antidepressants. J Clin Psychiatry 1993;54(Suppl): 16-22
6. Roose SP, Glassman AH, Giardina EG, et al. Tricyclic antidepressants in depressed patients with cardiac conduction disease. Arch Gen Psychiatry 1987;44(3): 273-5
7. Roose SP. Treatment of depression in patients with heart disease. Biol Psychiatry 2003;54(3): 262-8
8. Acikalin A, Satar S, Avc A, et al. QTc intervals in drug poisoning patients with tricyclic antidepressants and selective serotonin reuptake inhibitors. Am J Ther 2010;17(1): 30-3
9. Rodriguez de la Torre B, Dreher J, Malevany I, et al. Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients. Ther Drug Monit 2001;23(4): 435-40
10. U.S. Food and Drug Administration. FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). Available from: http://www.fda.gov/drugs/drugsafety/ ucm269086.html [Accessed on February 2013]
11. U.S. Food and Drug Administration. FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: http://www.fda.gov/drugs/drugsafety/ ucm297391.html [Accessed on February 2013]
12. MHRA. Citalopram and escitalopram: QT interval prolongation-new maximum daily dose restrictions (including in elderly patients), contraindications, and warnings. Drug Saf Update 2011;5(5):A1
13. Al-Khatib SM, LaPointe NM, Kramer JM, Califf RM. What clinicians should know about the QT interval. JAMA 2003;289(16): 2120-7
14. Haddad PM, Anderson IM. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 2002;62(11): 1649-71
15. Minns AB, Clark RF. Toxicology and overdose of atypical antipsychotics. J Emerg Med 2012;43(5): 906-13
16. Hunter JG, Burger J, Cooper KR. Use of an integrated mercury food web model for ecological risk assessment. J Environ Sci Health A Tox Hazard Subst Environ Eng 2003;38(7): 1201-14
17. Chan A, Isbister GK, Kirkpatrick CM, Dufful SB. Drug-induced QT prolongation and torsades de pointes: evaluation of a QT nomogram. QJM 2007;100(10): 609-15
18. Waring WS, Graham A, Gray J, et al. Evaluation of a QT nomogram for risk assessment after antidepressant overdose. Br J Clin Pharmacol 2010;70(6): 881-5
19. Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004;24(1): 62-9
20. Nielsen J, Graff C, Hardahl T, et al. Sertindole causes distinct electrocardiographic T-wave morphology changes. Eur Neuropsychopharmacol 2009;19(10): 702-7
21. Nielsen J, Andersen MP, Graff C, et al. The effect of sertindole on QTD and TPTE. Acta Psychiatr Scand 2010;121(5): 385-8
22. Kittnar O, Paclt I, Mlcek M, et al. QT dispersion and electrical heart field morphology in patients treated with dosulepin. Physiol Res 2004;53(4): 379-86
23. Turner AW, Malik M. Risk stratification and prediction of sudden death following myocardial infarction. Herz 1995;20(3): 200-12
24. Rasmussen SL, Overo KF, Tanghoj P. Cardiac safety of citalopram: prospective trials and retrospective analyses. J Clin Psychopharmacol 1999;19(5): 407-15
25. Zivin K, Pfeiffer PN, Bohnert AS, et al. Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg. Am J Psychiatry 2013;170(6):642-50
26. Leonard CE, Bilker WB, Newcomb C, et al. Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia. Pharmacoepidemiol Drug Saf 2011;20(9): 903-13
27. Martinez C, Assimes TL, Mines D, et al. Use of venlafaxine compared with other antidepressants and the risk of sudden cardiac death or near death: a nested case-control study. BMJ 2010;340:c249
28. McKean AJ, Sola CL, Galardy C, et al. Reconciling the risk of QT interval prolongation in antidepressants. Pharmacoepidemiol Drug Saf 2012;21(3):329-30; author reply 331-322
29. Leonard CE, Bilker WB, Newcomb C, et al. Additional data on citalopram and the risk of sudden cardiac death and ventricular arrhythmia. Pharmacoepidemiol Drug Saf 2012;21:331-2
30. Weeke P, Jensen A, Folke F, et al. Antidepressant use and risk of out-of-hospital cardiac arrest: a nationwide case-time-control study. Clin Pharmacol Ther 2012;92(1):72-9
31. Castro VM, Clements CC, Murphy SN, et al. QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ 2013;346:f288
32. Vieweg WV, Hasnain M, Howland RH, et al. Citalopram, QTc interval prolongation, and torsade de pointes. How should we apply the recent FDA ruling? Am J Med 2012;125(9): 859-68
33. Astrom-Lilja C, Odeberg JM, Ekman E, Hagg S. Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database. Pharmacoepidemiol Drug Saf 2008;17(6): 587-92
34. Tiihonen J, Lonnqvist J, Wahlbeck K, et al. Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort. Arch Gen Psychiatry 2006;63(12): 1358-67
35. Hawton K, Bergen H, Simkin S, et al. Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose. Br J Psychiatry 2010;196(5): 354-8
36. Isbister GK, Bowe SJ, Dawson A, Whyte IM. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol 2004;42(3): 277-85
37. Cheeta S, Schifano F, Oyefeso A, et al. Antidepressant-related deaths and antidepressant prescriptions in England and Wales, 1998-2000. Br J Psychiatry 2004;184: 41-7
38. Mason J, Freemantle N, Eccles M. Fatal toxicity associated with antidepressant use in primary care. Br J Gen Pract 2000;50(454): 366-70
39. Bergen H, Murphy E, Cooper J, et al. A comparative study of non-fatal selfpoisoning with antidepressants relative to prescribing in three centres in England. J Affect Disord 2010;123(1-3): 95-101
40. Reeves RR, Ladner ME. Antidepressant-induced suicidality: an update. CNS Neurosci Ther 2010;16(4): 227-34
41. Wenzel-Seifert K, Wittmann M, Haen E. Torsade de Pointes episodes under treatment with selective serotonin reuptake inhibitors. Pharmacopsychiatry 2010;43(7): 279-81
42. Liang S, Friedman LS. Analysis of suspected suicides using poison center data. Arch Suicide Res 2011;15(3): 185-94
43. Olmer A, Iancu I, Strous RD. Exposure to antidepressant medications and suicide attempts in adult depressed inpatients. J Nerv Ment Dis 2012;200(6): 531-4
44. Waring WS. Clinical use of antidepressant therapy and associated cardiovascular risk. Drug Healthc Patient Saf 2012;4: 93-101
45. Hyttel J, Bogeso KP, Perregaard J, Sanchez C. The pharmacological effect of citalopram residues in the (S)-(+)- enantiomer. J Neural Transm Gen Sect 1992;88(2): 157-60
46. Isbister GK, Friberg LE, Duffull SB. Application of pharmacokinetic- pharmacodynamic modelling in management of QT abnormalities after citalopram overdose. Intensive Care Med 2006;32(7): 1060-5
47. Sala M, Lazzaretti M, De Vidovich G, et al. Electrophysiological changes of cardiac function during antidepressant treatment. Ther Adv Cardiovasc Dis 2009;3(1): 29-43
48. Friberg LE, Isbister GK, Duffull SB. Pharmacokinetic-pharmacodynamic modelling of QT interval prolongation following citalopram overdoses. Br J Clin Pharmacol 2006;61(2): 177-90
49. Friberg LE, Isbister GK, Hackett LP, Duffull SB. The population pharmacokinetics of citalopram after deliberate self-poisoning: a Bayesian approach. J Pharmacokinet Pharmacodyn 2005;32(3-4): 571-605
50. Thomas D, Karle CA, Kiehn J. The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications. Curr Pharm Des 2006;12(18): 2271-83
51. Staudacher I, Wang L, Wan X, et al. hERG K+ channel-associated cardiac effects of the antidepressant drug desipramine. Naunyn Schmiedebergs Arch Pharmacol 2011;383(2): 119-39
52. Hong HK, Park MH, Lee BH, Jo SH. Block of the human ether-a-go-go-related gene (hERG) K+ channel by the antidepressant desipramine. Biochem Biophys Res Commun 2010;394(3): 536-41
53. Fossa AA, Gorczyca W, Wisialowski T, et al. Electrical alternans and hemodynamics in the anesthetized guinea pig can discriminate the cardiac safety of antidepressants. J Pharmacol Toxicol Methods 2007;55(1): 78-85
54. Witchel HJ, Pabbathi VK, Hofmann G, et al. Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular L-type calcium currents. FEBS Lett 2002;512(1-3): 59-66
55. Vieweg WV, Wood MA, Fernandez A, et al. Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly. Drugs Aging 2009;26(12): 997-1012
56. Mojtabai R, Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry 2010;67(1): 26-36
57. Bauer M, Whybrow PC, Angst J, et al. World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 2002;3(1): 5-43
58. Anderson IM, Ferrier IN, Baldwin RC, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 2008;22(4): 343-96
59. CredibleMeds. Available from: http://www.azcert.org/index.cfm [Accessed on 28 January 2013]